Dr. James W. Sublett, M.D.

Medicare patients and services

Medicare patients, 2024

390

Services billed

22,446

Patients’ average age

72

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 22 companies reported 160 payments worth $138,465 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Kentucky →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 7 companies. The companies reported $197,608 in research payments for these studies, mostly to the institutions running them.

• A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
  Amgen Inc.
• The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
  AstraZeneca Pharmaceuticals LP
• A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Contro…
  Novartis Pharmaceuticals Corporation
• A phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma
  AstraZeneca UK Limited
• Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
  Genzyme Corporation · Active, not recruiting · NCT05097287
• A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
  AstraZeneca Pharmaceuticals LP
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06572228
• A prospective, real-world, interventional study to evaluate the effect
  GlaxoSmithKline, LLC.
• A randomized, double-blind, parallel group, multi-center study to eval
  GlaxoSmithKline, LLC.
• A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared …
  AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Allergy & Immunology clinicians in Louisville

• Ashley M. Ciliberti, M.D.
• Mark L. Corbett, M.D.
• Damon B. Coyle, M.D.
• Alexander G. Emerson, MD
• Timothy A. Feger, MD
• Timothy J. Franxman, M.D.
• Daniel P. Garcia, MD
• Jennifer E. Gentner, MD